Catalog
Client
Theme:
0 0
Catalog
Main page
Wishlist
0
Compare
0
Contacts

Eprex 4000IU Janssen-Cilag

Brand: Janssen-Cilag Product Code: EU12728
0
All about product
Description
Specification
Reviews 0
Questions0
Out Of Stock
€264.00
Active substance: Epoetin Alfa (Erythropoietin)
Also known as: EPO
Blood pressure: Can cause an increase in blood pressure
Chemical name: Erythropoietin
Dosage (medical): Typically 50-300 units/kg three times a week, dose adjusted based on hemoglobin levels and patient response
Eprex 4000IU Janssen-Cilag
Eprex 4000IU Janssen-Cilag
€264.00
Description
Specifications
Features
Active substance
Epoetin Alfa (Erythropoietin)
Also known as
EPO
Blood pressure
Can cause an increase in blood pressure
Chemical name
Erythropoietin
Dosage (medical)
Typically 50-300 units/kg three times a week, dose adjusted based on hemoglobin levels and patient response
Dosage (sports)
Misuse can involve 20-50 IU/kg of body weight, three times per week
Effects
Increases red blood cell count, enhances oxygen transport and aerobic capacity
Formula
Not applicable as it is a glycoprotein
Half-life
Varies, typically 4-13 hours depending on the type (recombinant forms)
Hepatotoxicity
None reported
Lab Test
Detection via specific blood tests (e.g., EPO doping test, isoelectric focusing)
Main action
Stimulates erythropoiesis (production of red blood cells)
Side effects
Hypertension, thrombosis, increased risk of stroke, headache, flu-like symptoms
Storage conditions
Refrigerated, typically between 2-8В°C
Substance class
Hormone, specifically a growth factor
Trade name
Epogen, Procrit, Eprex, others
Use in sports
Banned - used to increase endurance and performance
Water Retention
Minimal
Manufacturer
Janssen-Cilag
Packing
1 pack (6 Prefilled Syringes (4000iu/0.4ml))
Reviews

There are no reviews for this product.

There are no reviews for this product, be the first to leave your review.

Answers & questions
Add your question and we will answer as soon as possible.

No questions about this product, be the first and ask your question.